证券代码：688298 证券简称：东方生物 公告编号：2025-034 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、变更注册（备案）的医疗器械注册证基本情况如下： | 产品名称 | 证书编号 | 预期用途 | 重要变更情况 | 变更生效 日期 | 持证 主体 | | --- | --- | --- | --- | --- | --- | | 幽门螺旋杆菌 抗原检测试剂 | 国械注准 | 本产品用于体外定性 检测人粪便中的幽门 | 1、产品有效期由"12个 月"变更为"24个月"； | 2025/6/12 | 新兴 | | | 20173401200 | | 2、增加自测预期用途； | | 四寰 | | 盒(胶体金法) | | 螺旋杆菌抗原 | | | | | | | | 3、增加包装规格 | | | 三、对上市公司的影响 公司呼吸道抗原联合检测试剂（自测/专业）在上述国家和地区获得注册，表 明上述产品已符合相关国家和地区要求，具备了该市场的准入 ...

Group 1 - The company announced a share repurchase plan with a total expected amount between RMB 25 million and RMB 50 million [1] - The repurchase period is set from June 26, 2025, to September 25, 2025 [1] - The maximum repurchase price is capped at RMB 32.44 per share [1] Group 2 - As of June 30, 2025, the company has not yet implemented the share repurchase [2] - The company will adhere to relevant regulations and disclose progress on the repurchase in a timely manner [2] - The repurchase is aimed at maintaining company value and protecting shareholder interests [1][2]

证券代码：688298 证券简称：东方生物 公告编号：2025-031 浙江东方基因生物制品股份有限公司 关于以集中竞价交易方式回购公司股份进展的公告 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，"在回购股份期间,上市公司应当在每个月的前三 个交易日内，公告截至上月末的回购进展情况"，现将公司回购股份进展情况公告 如下： 截至 2025 年 6 月 30 日，公司尚未实施本期股份回购。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/28 | | | | | | | | --- | --- | --- | --- | -- ...

Group 1 - The company plans to repurchase its shares using an amount not less than RMB 25 million and not exceeding RMB 50 million through centralized bidding within a period of up to 3 months from the board's approval of the repurchase plan [2][1] - The repurchase is in compliance with relevant laws and regulations, including the "Regulations on the Repurchase of Shares by Listed Companies" and the "Self-Regulatory Guidelines for Listed Companies No. 7 - Share Repurchase" [2][1] - The supervisory board has confirmed that the repurchase plan is in the interest of all shareholders, particularly minority shareholders, and that the decision-making process is legal and compliant [2][1]

Core Viewpoint - The company plans to repurchase shares with an amount ranging from RMB 25 million to RMB 50 million to maintain company value and shareholder rights [1][3][4] Summary by Sections Repurchase Plan Details - The repurchase amount will not be less than RMB 25 million and not exceed RMB 50 million [1][4] - The funding source for the repurchase will be entirely from self-owned or self-raised funds, including special loans for stock repurchase [1][8] - The maximum repurchase price is set at RMB 32.44 per share, which does not exceed 130% of the average trading price over the last 30 trading days prior to the board's decision [1][4][6] - The repurchase will be conducted through centralized bidding and is expected to be completed within three months from the board's approval [1][5][6] Purpose and Use of Repurchased Shares - The repurchased shares will be used to maintain company value and shareholder rights, and will be sold within 12 months after the repurchase results are disclosed [1][4][13] - If the company fails to sell the shares within the stipulated time, the unsold shares will be canceled [1][4][13] Shareholder and Management Plans - The controlling shareholders and key management personnel have no plans to reduce their holdings during the repurchase period and the following three to six months [2][12] - The financial officer indicated a potential for share reduction in the future, subject to legal requirements [2][12] Implementation and Regulatory Compliance - The repurchase plan was approved by the board on June 26, 2025, and does not require further shareholder approval [3][4] - The company will adjust the repurchase terms in accordance with any changes in national policies [1][4][15] - The company has obtained a loan commitment from a bank to support the repurchase [8][10] Financial Impact - The repurchase amount will represent approximately 0.38% to 0.76% of the total share capital, depending on the final number of shares repurchased [6][7] - The total assets of the company as of March 31, 2025, were RMB 775.92 million, with a net asset value of RMB 652.18 million, indicating that the repurchase will not significantly impact the company's financial stability [10][11]

证券代码：688298 证券简称：东方生物 公告编号：2025-030 浙江东方基因生物制品股份有限公司 会议由监事方晓萍女士主持召开，全体与会监事经认真审议和表决，形成以 下决议： 1、审议通过《关于以集中竞价交易方式回购公司股份的方案》 表决结果：本议案有效表决票 3 票，3 票同意，0 票反对，0 票弃权。 公司监事会认为：本次公司使用不低于人民币 2,500 万元（含），不超过人 民币 5,000 万元（含）的自有资金或自筹资金（含股票回购专项贷款资金等）， 以集中竞价交易方式回购公司股份，回购期限为自董事会审议通过本次股份回购 方案之日起不超过 3 个月。符合《上市公司股份回购规则》《上海证券交易所上 市公司自律监管指引第 7 号——回购股份》等法律法规、规范性文件的有关规定， 符合公司全体股东利益，不存在损害公司及股东尤其是中小股东利益的情形，该 议案的审议程序合法合规。公司监事会同意本次以集中竞价交易方式回购公司股 份的事项。 具体内容详见公司于同日在上海证券交易所网站(http://www.sse.com.cn) 披露的《关于以集中竞价交易方式回购公司股份的方案》（公告编号 2025-028） ...

证券代码：688298 证券简称：东方生物 公告编号：2025-029 表决情况：同意 7 票、反对 0 票、弃权 0 票。 具体内容详见公司于同日在上海证券交易所网站(http://www.sse.com.cn) 披露的《关于以集中竞价交易方式回购股份的方案》（公告编号 2025-028）。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"公司"）第三届董事会第 十三次会议于 2025 年 6 月 23 日以电子邮件的形式发出会议通知，于 2025 年 6 月 26 日上午 9:00 在公司会议室以现场会议加通讯表决的方式召开。会议应出席 董事 7 名，实到出席董事 7 名。会议召开符合法律法规、《公司法》及《公司章 程》的相关规定。 会议由董事长方剑秋先生主持召开，全体与会董事经认真审议和表决，形成 以下决议： 1、审议通过《关于以集中竞价交易方式回购公司股份的方案》 董事会同意公司使用不低于人民币 2,500 万元（含），不超过人民币 5,000 万元（含）的自 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-028 浙江东方基因生物制品股份有限公司 关于以集中竞价方式回购公司股份的方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 2,500 万元（含），不超过人民币 5,000 万元（含）； ● 回购股份资金来源：本次回购股份的资金来源全部为自有资金或自筹资金（含 股票回购专项贷款资金等）； ● 回购股份用途：本次回购的股份将用于维护公司价值及股东权益，将在公司披 露回购结果暨股份变动公告 12 个月后采用集中竞价交易方式出售，并在 3 年内完 成出售。公司如未能在规定期限内完成出售，未出售部分将履行相关程序予以注 销。如国家对相关政策作调整，则本回购方案按调整后的政策实行； ● 回购股份价格：不超过 32.44 元，该价格未超过董事会通过回购股份决议前 30 个交易日公司股票交易均价的 130%； ● 回购股份方式：以集中竞价的方式； ● 回购股份期限：自董事会审议通过本次股份回购方案之日起不超过 3 个月； ...

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

证券代码：688298 证券简称：东方生物 公告编号：2025-027 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 三、对上市公司的影响 全自动免疫印记分析仪主要用于过敏源检测试剂、自免检测试剂等配套使用。 PSA证书的取得，进一步丰富了公司在欧盟肿瘤标志物检测领域的技术路径及 产品系列，主要用于前列腺癌的检测和患者筛查、复发检测、诊断后监测和治疗 监测等管理。 上述产品的取证有利于国内外市场的整体拓展。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 及子公司杭州深度生物科技有限公司近日取得以下医疗器械注册证（体外诊断试 剂），相关证书内容公告如下： 一、中国医疗器械注册取证主要内容如下： | 产品名称 | 证书编号 | 预期用途 | 有效期 | 持证主体 | | --- | --- | --- | --- | --- | | 全自动免疫印迹分析仪 | 浙械注准 20252221447 | 基于免疫印迹原理，与适配测 试剂配合 ...